JAK2 and Hodgkins lymphoma: Actually, the JAK2 selective inhibitor, fedratinib decreased the cellular proliferation of HL and PMBCL cell lines, and reduced tumor growth in murine xenograft models of cHL and MLBCL with 9p24.1/JAK2 amplification [14].